Research programme: anti-infectives - BioDiem

Drug Profile

Research programme: anti-infectives - BioDiem

Alternative Names: BDM-I; BMD I; OPAL-I; OPAL-T

Latest Information Update: 20 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer BioDiem; QIMR Berghofer Medical Research Institute; United States Army Medical Research Institute of Infectious Diseases
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Bacterial infections; Schistosomiasis
  • Research Mycoses

Most Recent Events

  • 20 Feb 2018 Anti-infectives are still in early research for Bacterial infections and Mycoses in Australia (BioDem pipeline, February 2018)
  • 20 Feb 2018 Anti-infectives are still in preclinical development for Schistosomiasis in Australia (BioDem pipeline, February 2018)
  • 20 Feb 2018 Anti-infectives are still in early research for Mycoses in USA (BioDem pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top